A 52-year-old man with hypertension presents to the emergency department with active anterior epistaxis. Local measures including head tilt, nasal packing with gauze soaked in 1:10,000 epinephrine, and 15 minutes of direct pressure have failed to control bleeding. Which drug should be administered systemically as first-line pharmacological management?

Explanation

## Systemic Pharmacological Management of Refractory Epistaxis **Key Point:** Tranexamic acid (TXA) is the first-line systemic drug for epistaxis that fails local measures, particularly when bleeding is brisk or recurrent. ### Mechanism of Action Tranexamic acid is an antifibrinolytic agent that inhibits plasminogen activation and fibrin degradation, stabilizing clot formation at the bleeding site. ### Dosing and Administration - **IV route:** 10–15 mg/kg bolus, then 1 mg/kg/hr infusion - **Oral route:** 1.5 g three times daily (for prophylaxis or mild bleeding) - **Topical route:** 500 mg/5 mL solution applied directly to bleeding site **High-Yield:** Recent meta-analyses and guidelines (including British Rhinological Society) recommend TXA as adjunctive therapy in moderate-to-severe epistaxis, reducing transfusion requirements and hospital stay. ### When to Use - Anterior epistaxis uncontrolled by local measures - Posterior epistaxis (especially in elderly or anticoagulated patients) - Recurrent epistaxis - Epistaxis in patients on anticoagulants or with coagulopathy ### Contraindications - Active thromboembolic disease (stroke, MI, DVT) - Hematuria (risk of clot retention in urinary tract) - Subarachnoid hemorrhage **Clinical Pearl:** TXA is safe in hypertensive patients (unlike vasopressin) and does not cause systemic vasoconstriction, making it ideal for this 52-year-old with hypertension. ### Comparison with Other Systemic Agents | Agent | Mechanism | Use in Epistaxis | Limitations | |-------|-----------|------------------|-------------| | **Tranexamic acid** | Antifibrinolytic | First-line systemic | Contraindicated in thromboembolism | | **Vasopressin** | V1 receptor agonist (vasoconstriction) | Posterior epistaxis (historical) | Hypertension, coronary ischemia, arrhythmias | | **Phenylephrine** | α1 agonist | Topical vasoconstriction only | Systemic use causes severe hypertension | | **Hydrocortisone** | Corticosteroid | Not indicated for acute control | Anti-inflammatory, no hemostatic effect | **Warning:** Vasopressin is contraindicated in hypertensive patients due to risk of hypertensive crisis and coronary vasospasm. Phenylephrine is a topical agent and should not be given systemically for epistaxis management.